FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maurice, M.
Right arrow Articles by Maurel, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maurice, M.
Right arrow Articles by Maurel, P.

The FASEB Journal, Vol 6, 752-758, Copyright © 1992 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture

M Maurice, L Pichard, M Daujat, I Fabre, H Joyeux, J Domergue and P Maurel
INSERM U-128, CNRS, Montpellier, France.

The expression of several forms of cytochrome P450 including P450 1A2, 2D6, 2E1, and 3A was investigated in human hepatocytes maintained in primary culture for 96 h in the absence or presence of 50 microM of various imidazole derivatives. These included ketoconazole, clotrimazole, miconazole, fluconazole, secnidazole and metronidazole. In addition, the typical inducers rifampicin and beta-naphthoflavone were used for comparison. Western and Northern blot analysis of microsomes and RNA prepared from these cultures as well as de novo synthesis experiments revealed that, among the imidazole derivatives tested, only clotrimazole was a strong rifampicin-like inducer of P450 3A. The expression of the other forms of P450 tested was not affected by the treatments. Analysis of the inhibition of 13 monoxygenase activities, including ethoxyresorufin and phenacetin O-deethylases, coumarin 7 alpha-, lauric acid 11- and 12-, mephenytoin 4-, debrisoquin 4-, and aniline hydroxylases, benzphetamine, aminopyrine, mephenytoin and erythromycin demethylases, and cyclosporin oxidase (representative of 10 different forms of P450 in human liver microsomes) revealed that ketoconazole was a strong and selective in vitro inhibitor of P450 3A (cyclosporin oxidase) with a Ki less than 1 microM. Clotrimazole and miconazole were also strong inhibitors of P450 3A-mediated activities in contrast to the other imidazole derivatives.


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
K. Dilger, R. Fux, D. Rock, K. Morike, and C. H. Gleiter
Effect of High-Dose Metronidazole on Pharmacokinetics of Oral Budesonide and Vice Versa: A Double Drug Interaction Study
J. Clin. Pharmacol., December 1, 2007; 47(12): 1532 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. K. Ogden, J. R. Falck, and S. W. Watts
The Cytochrome P450 Inhibitor Ketoconazole Potentiates 5-Hydroxytryptamine-Induced Contraction in Rat Aorta
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 606 - 613.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. Cai, R. Tsao, and M. E. Ruppen
In Vitro Metabolic Study of Temsirolimus: Preparation, Isolation, and Identification of the Metabolites
Drug Metab. Dispos., September 1, 2007; 35(9): 1554 - 1563.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. Roedler, M. M Neuhauser, and S. R Penzak
Does Metronidazole Interact with CYP3A Substrates by Inhibiting Their Metabolism Through This Metabolic Pathway? Or Should Other Mechanisms Be Considered?
Ann. Pharmacother., April 1, 2007; 41(4): 653 - 658.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. N. Tipre, S. S. Zoghbi, J.-S. Liow, M. V. Green, J. Seidel, M. Ichise, R. B. Innis, and V. W. Pike
PET Imaging of Brain 5-HT1A Receptors in Rat In Vivo with 18F-FCWAY and Improvement by Successful Inhibition of Radioligand Defluorination with Miconazole
J. Nucl. Med., February 1, 2006; 47(2): 345 - 353.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. P. Yong, J. Ramirez, F. Innocenti, and M. J. Ratain
Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes
Clin. Cancer Res., September 15, 2005; 11(18): 6699 - 6704.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. L. Page II, P. M Klem, and C. Rogers
Potential Elevation of Tacrolimus Trough Concentrations with Concomitant Metronidazole Therapy
Ann. Pharmacother., June 1, 2005; 39(6): 1109 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. Shuster, J. Meynadier, H. Kerl, and S. Nolting
Treatment and Prophylaxis of Seborrheic Dermatitis of the Scalp With Antipityrosporal 1% Ciclopirox Shampoo
Arch Dermatol, January 1, 2005; 141(1): 47 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. V. Karanam, C. J. Welch, V. G. Reddy, J. Chilenski, M. Biba, and S. Vincent

Drug Metab. Dispos., October 1, 2004; 32(10): 1061 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. V. Karanam, C. E.C.A. Hop, D. Q. Liu, M. Wallace, D. Dean, H. Satoh, M. Komuro, K. Awano, and S. H. Vincent

Drug Metab. Dispos., September 1, 2004; 32(9): 1015 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. C. Komen, M. Duran, and R. J. A. Wanders
{omega}-Hydroxylation of phytanic acid in rat liver microsomes: implications for Refsum disease
J. Lipid Res., July 1, 2004; 45(7): 1341 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. Jager, T. Dreker, A. Buck, K. Giehl, T. Gress, and S. Grissmer
Blockage of Intermediate-Conductance Ca2+-Activated K+ Channels Inhibit Human Pancreatic Cancer Cell Growth in Vitro
Mol. Pharmacol., March 1, 2004; 65(3): 630 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. M. Stresser, M. I. Broudy, T. Ho, C. E. Cargill, A. P. Blanchard, R. Sharma, A. A. Dandeneau, J. J. Goodwin, S. D. Turner, J. C. L. Erve, et al.
HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE
Drug Metab. Dispos., January 1, 2004; 32(1): 105 - 112.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
V. Hatorp, K. T. Hansen, and M. S. Thomsen
Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide
J. Clin. Pharmacol., June 1, 2003; 43(6): 649 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al.
Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes
Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Yamamoto, N. Hagima, M. Nakamura, Y. Kohno, K. Nagata, and Y. Yamazoe
Differences in Cytochrome P450 Forms Involved in the Metabolism of N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a Novel Sigma Ligand, in Human Liver and Intestine
Drug Metab. Dispos., January 1, 2003; 31(1): 60 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. A. Kliewer, B. Goodwin, and T. M. Willson
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Endocr. Rev., October 1, 2002; 23(5): 687 - 702.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Takeshita, M. Taguchi, N. Koibuchi, and Y. Ozawa
Putative Role of the Orphan Nuclear Receptor SXR (Steroid and Xenobiotic Receptor) in the Mechanism of CYP3A4 Inhibition by Xenobiotics
J. Biol. Chem., August 30, 2002; 277(36): 32453 - 32458.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Zhang, Y. Ramamoorthy, T. Kilicarslan, H. Nolte, R. F. Tyndale, and E. M. Sellers
Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives
Drug Metab. Dispos., March 1, 2002; 30(3): 314 - 318.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Ayabe, H. Wulff, D. Darmoul, M. D. Cahalan, K. G. Chandy, and A. J. Ouellette
Modulation of Mouse Paneth Cell alpha -Defensin Secretion by mIKCa1, a Ca2+-activated, Intermediate Conductance Potassium Channel
J. Biol. Chem., January 25, 2002; 277(5): 3793 - 3800.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. J. Myers, D. E. Farrell, K. D. Howard, and J. C. Kawalek
Identification of Multiple Constitutive and Inducible Hepatic Cytochrome P450 Enzymes in Market Weight Swine
Drug Metab. Dispos., June 1, 2001; 29(6): 908 - 915.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M.-S. Baek, J.-Y. Kim, S.-W. Myung, Y. H. Yim, J.-H. Jeong, and D.-H. Kim
Metabolism of Dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) by Human Liver Microsomes: Characterization of Metabolic Pathways and of Cytochrome P450 Isoforms Involved
Drug Metab. Dispos., April 1, 2001; 29(4): 381 - 388.
[Abstract] [Full Text]

Home page
 J Med MicrobiolHome page
C.A. HART, N.J. BEECHING, and B.I. DUERDEN
Infections in AIDS: Proceedings of the Sixth Liverpool Tropical School Bayer Symposium on Microbial Diseases held on 6 February 1999
J. Med. Microbiol., November 1, 2000; 49(11): 947 - 967.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. B. Renwick, P. S. Watts, R. J. Edwards, P. T. Barton, I. Guyonnet, R. J. Price, J. M. Tredger, O. Pelkonen, A. R. Boobis, and B. G. Lake
Differential Maintenance of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices
Drug Metab. Dispos., October 1, 2000; 28(10): 1202 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Sueyasu, K. Fujito, H. Shuto, T. Mizokoshi, Y. Kataoka, and R. Oishi
Protein Binding and the Metabolism of Thiamylal Enantiomers In Vitro
Anesth. Analg., September 1, 2000; 91(3): 736 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Wulff, M. J. Miller, W. Hansel, S. Grissmer, M. D. Cahalan, and K. G. Chandy
Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: A potential immunosuppressant
PNAS, July 5, 2000; 97(14): 8151 - 8156.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. J. Rodriguez, P. J. Proteau, B. L. Marquez, C. L. Hetherington, C. J. Buckholz, and K. L. O'Connell
Flavin-Containing Monooxygenase-Mediated Metabolism of N-Deacetyl Ketoconazole by Rat Hepatic Microsomes
Drug Metab. Dispos., August 1, 1999; 27(8): 880 - 886.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Ludwig, J. Schmid, K. Beschke, and T. Ebner
Activation of Human Cytochrome P-450 3A4-Catalyzed Meloxicam 5'-Methylhydroxylation by Quinidine and Hydroquinidine In Vitro
J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 1 - 8.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. Bourrié, V. Meunier, Y. Berger, and G. Fabre
Role of Cytochrome P-4502C9 in Irbesartan Oxidation by Human Liver Microsomes
Drug Metab. Dispos., February 1, 1999; 27(2): 288 - 296.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. M. Gentile, C. H. J. Verhoeven, T. Shimada, and D. J. Back
The Role of CYP2C in the In Vitro Bioactivation of the Contraceptive Steroid Desogestrel
J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 975 - 982.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
B. V. Karanam, R. R. Miller, A. Colletti, T. Montgomery, K. D. Carey, T. Hawkins, Y. S. Tang, M. Lavin, R. A. Stearns, S. H. L. Chiu, et al.
Disposition of L-732,531, a Potent Immunosuppressant, in Rats and Baboons
Drug Metab. Dispos., October 1, 1998; 26(10): 949 - 957.
[Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
A. Cato III, J. Qian, A. Hsu, B. Levy, J. Leonard, and R. Granneman
Multidose Pharmacokinetics of Ritonavir and Zidovudine in Human Immunodeficiency Virus-Infected Patients
Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1788 - 1793.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Hashizume, M. Mise, Y. Terauchi, L. O, T. Fujii, H. Miyazaki, and T. Inaba
N-Dealkylation and Hydroxylation of Ebastine by Human Liver Cytochrome P450
Drug Metab. Dispos., June 1, 1998; 26(6): 566 - 571.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
H. Postlind, A. Danielson, A. Lindgren, and S. H. G. Andersson
Tolterodine, a New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes
Drug Metab. Dispos., April 1, 1998; 26(4): 289 - 293.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
A. Cato III, G. Cao, A. Hsu, J. Cavanaugh, J. Leonard, and R. Granneman
Evaluation of the Effect of Fluconazole on the Pharmacokinetics of Ritonavir
Drug Metab. Dispos., September 1, 1997; 25(9): 1104 - 1106.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
H. G. Oldham and S. E. Clarke
In vitro Identification of the Human Cytochrome P450 Enzymes Involved in the Metabolism of R(+)- and S(-)-Carvedilol
Drug Metab. Dispos., August 1, 1997; 25(8): 970 - 977.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
J. C. Bloomer, S. E. Clarke, and R. J. Chenery
In vitro Identification of the P450 Enzymes Responsible for the Metabolism of Ropinirole
Drug Metab. Dispos., July 1, 1997; 25(7): 840 - 844.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The Federation of American Societies for Experimental Biology.